Do NMDA receptor antibodies alter synaptic signaling and cause autoimmune neuropsychiatric syndromes?

Immunoglobulin G (IgG) autoantibodies targeting the NMDA receptor (NMDAR) are established drivers of severe neuroinflammatory and neuropsychiatric pathology, with distinct clinical implications across the lifespan.

Molecular and Synaptic Mechanisms

• Receptor Internalization: Pathogenic, bivalent IgG antibodies bind specifically to extracellular epitopes on the GluN1 subunit of the NMDAR. This binding cross-links the receptors, disrupting their stabilizing interaction with the receptor tyrosine kinase EphB2 at the postsynaptic density.
• Synaptic Depletion: Unstabilized NMDARs redistribute laterally to extrasynaptic sites and undergo rapid, clathrin-mediated endocytosis. This selective depletion reduces postsynaptic NMDAR-mediated currents and impairs long-term potentiation (LTP) at Schaffer collateral–CA1 synapses.
• Network Disinhibition: The loss of NMDARs on inhibitory GABAergic interneurons reduces their firing. This disinhibits glutamatergic projection neurons and shifts the global network toward a hyperglutamatergic state. These pathological alterations are highly isotype-specific, driven by IgG but not IgA or IgM.

Clinical and Neuropsychiatric Manifestations

• Encephalitis Presentation: This NMDAR hypofunction directly causes anti-NMDA receptor encephalitis. The resulting clinical syndrome is characterized by rapid-onset psychosis, catatonia, memory deficits, seizures, and autonomic instability.
• Age-Specific Profiles: Although more common in younger populations, the syndrome is well-documented in older adults (such as males in their seventh decade), where it frequently presents as atypical cognitive decline and carries a higher risk of underlying malignancy. Standardized diagnosis under Graus criteria requires confirming the presence of IgG anti-GluN1 antibodies, which yields superior specificity in cerebrospinal fluid (CSF) compared to serum.

Bottom line

• Pathogenic IgG antibodies against the NMDAR GluN1 subunit disrupt synaptic signaling via receptor internalization and network disinhibition, directly causing anti-NMDA receptor encephalitis—a severe autoimmune neuropsychiatric syndrome requiring prompt CSF antibody confirmation.